
Quarterly ResultNov 5, 2026, 07:13 AM
Avalo Therapeutics Reports Q3 2026 Results; Cash Runway to 2029
AI Summary
Avalo Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $18.9 million ($0.34 per share). The company highlighted its strong cash position of $462.8 million, sufficient to fund operations into 2029. Key business updates include advancing abdakibart towards a Phase 3 program for hidradenitis suppurativa and AVTX-010 towards an IND submission, both anticipated in the first half of 2027.
Key Highlights
- Avalo Therapeutics reported Q3 2026 net loss of $18.9 million, or $0.34 per share.
- Cash, cash equivalents, and investments totaled $462.8 million as of September 30, 2026, expected to fund operations into 2029.
- Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for H1 2027.
- Advancing AVTX-010 toward an Investigational New Drug submission in H1 2027.
- Research and development expenses were $15.0 million for Q3 2026.
- General and administrative expenses were $8.4 million for Q3 2026.
Price Impact
More from AVTX